Market Cap 15.21B
Revenue (ttm) 814.76M
Net Income (ttm) -258.00M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 55.92
Profit Margin -31.67%
Debt to Equity Ratio 1.84
Volume 622,900
Avg Vol 701,626
Day's Range N/A - N/A
Shares Out 62.38M
Stochastic %K 17%
Beta 0.37
Analysts Strong Sell
Price Target $307.78

Company Profile

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clini...

Industry: Biotechnology
Sector: Healthcare
Phone: 45 70 22 22 44
Address:
Tuborg Boulevard 12, Hellerup, Denmark
JamesTaulman
JamesTaulman Aug. 3 at 2:28 PM
MON 8/3: $ASND – CALLING A 2ND SELL SIGNAL @ $240.85 -4.0% 9:37 AM – Calling a 2ND SELL SIGNAL this morning (correction: the earlier email incorrectly stated a 1st SELL SIGNAL) as shares are clearly breaking below the 50 DMA. This loss of a major support level represents a meaningful technical violation and warrants further reducing the position. ULTRA Trader’s Tip: Major Support Levels Matter • The 50 DMA often serves as an important line of institutional support. • When a stock decisively breaks below that level, the probability of continued weakness increases. • Respecting major technical violations early helps preserve capital and keeps small losses from becoming much larger ones. https://buyingbreakouts.com/mon-8-3-asnd-calling-a-2nd-sell-signal-240-85-4-0/
0 · Reply
JamesTaulman
JamesTaulman Aug. 1 at 3:16 AM
FRI 7/31: $ASND – Any Further Declines Would Be the Final Sell Signal 7:50 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-7-31-asnd-any-further-declines-would-be-the-final-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 31 at 2:11 AM
THU 7/30: $ASND – A Break of the 50 DMA at $244.50 is a Long Overdue Sell Signal 7:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-30-asnd-a-break-of-the-50-dma-at-244-50-is-a-long-overdue-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 29 at 3:27 AM
TUE 7/28: $ASND – Rallies Into the Close but Remains Below Its Proven 10 DMA Resistance 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-7-28-asnd-rallies-into-the-close-but-remains-below-its-proven-10-dma-resistance/
0 · Reply
SenefAS
SenefAS Jul. 28 at 3:10 PM
When is the buyout and this high premium for Ascendis $ASND ? @bharringtonw11 $XBI $NVO
0 · Reply
JamesTaulman
JamesTaulman Jul. 28 at 2:04 AM
MON 7/27: $ASND – Makes for a Great Example of 10 DMA Resistance 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-27-asnd-makes-for-a-great-example-of-10-dma-resistance/
0 · Reply
JamesTaulman
JamesTaulman Jul. 25 at 4:02 AM
FRI 7/24: $ASND – The 10 DMA Just Keeps Crushing This Stock – a Break of the Round-$250 Would Be a Sell Signal 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-7-24-asnd-the-10-dma-just-keeps-crushing-this-stock-a-break-of-the-round-250-would-be-a-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 24 at 2:16 AM
THU 7/23: $ASND – Remains Above Our Noted Support of the Round-$250 – the 10 DMA Line Has Clearly Rolled Over – Not Good 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-23-asnd-remains-above-our-noted-support-of-the-round-250-the-10-dma-line-has-clearly-rolled-over-not-good/
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:44 PM
Morgan Stanley, in a broad research note earnings preview, ⬆️ $ASND to $275 from $256, reiterated (reit'd) Overweight; $DNLI to $36 from $35, reit'd Overweight; $EXEL to $53 from $50, reit'd Equal Weight; and $INCY to $104 from $103, reit'd Equal Weight, and said 2Q26 earnings should reinforce a shift from macro-driven trading toward stock-specific execution and differentiation.
0 · Reply
JamesTaulman
JamesTaulman Jul. 23 at 3:05 AM
WED 7/22: $ASND – A Break Below the Round-$250 Would Be a 2nd Sell Signal 9:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-22-asnd-a-break-below-the-round-250-would-be-a-2nd-sell-signal/
0 · Reply
Latest News on ASND
Ascendis Pharma added to multiple Russell U.S. Indexes

2026-06-26T20:25:11.000Z - 5 weeks ago

Ascendis Pharma added to multiple Russell U.S. Indexes


Ascendis Pharma completes Phase 3 PaTHway Trial

2026-06-14T20:40:05.000Z - 7 weeks ago

Ascendis Pharma completes Phase 3 PaTHway Trial


Ascendis Pharma initiated with a Buy at Citi

2026-05-18T20:26:36.000Z - 2 months ago

Ascendis Pharma initiated with a Buy at Citi


Ascendis Pharma Earnings Call Transcript: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Ascendis Pharma Earnings Call Transcript: Q1 2026


Ascendis Pharma Earnings release: Q1 2026

May 7, 2026, 8:00 AM EDT - 3 months ago

Ascendis Pharma Earnings release: Q1 2026


Ascendis Pharma Reports First Quarter 2026 Financial Results

May 7, 2026, 7:30 AM EDT - 3 months ago

Ascendis Pharma Reports First Quarter 2026 Financial Results


Ascendis Pharma price target raised to $292 from $262 at BofA

2026-04-16T11:52:18.000Z - 3 months ago

Ascendis Pharma price target raised to $292 from $262 at BofA


Ascendis Pharma to list ordinary shares directly on Nasdaq

2026-04-08T16:07:08.000Z - 4 months ago

Ascendis Pharma to list ordinary shares directly on Nasdaq


Ascendis Pharma to List Ordinary Shares Directly on Nasdaq

Apr 8, 2026, 12:00 PM EDT - 4 months ago

Ascendis Pharma to List Ordinary Shares Directly on Nasdaq


Ascendis Pharma announces new data from COACH trial

2026-04-08T12:17:11.000Z - 4 months ago

Ascendis Pharma announces new data from COACH trial


Ascendis Pharma Transcript: FDA announcement

Mar 2, 2026, 8:00 AM EST - 5 months ago

Ascendis Pharma Transcript: FDA announcement


Ascendis Pharma Press release: FDA announcement

Mar 2, 2026, 8:00 AM EST - 5 months ago

Ascendis Pharma Press release: FDA announcement


Ascendis Pharma Slides: FDA announcement

Mar 2, 2026, 8:00 AM EST - 5 months ago

Ascendis Pharma Slides: FDA announcement


Ascendis Pharma Earnings Call Transcript: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Earnings Call Transcript: Q4 2025


Ascendis Pharma Annual report: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Annual report: Q4 2025


Ascendis Pharma Earnings release: Q4 2025

Feb 11, 2026, 4:30 PM EST - 6 months ago

Ascendis Pharma Earnings release: Q4 2025


Ascendis Pharma Transcript: Study Update

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Transcript: Study Update


Ascendis Pharma Press release: Study Update

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Press release: Study Update


Ascendis Pharma Slides: Study Update

Jan 8, 2026, 4:30 PM EST - 7 months ago

Ascendis Pharma Slides: Study Update


Ascendis Pharma Earnings Call Transcript: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Ascendis Pharma Earnings Call Transcript: Q3 2025


Ascendis Pharma Earnings release: Q3 2025

Nov 12, 2025, 4:30 PM EST - 9 months ago

Ascendis Pharma Earnings release: Q3 2025


Ascendis Pharma Reports Third Quarter 2025 Financial Results

Nov 12, 2025, 4:01 PM EST - 9 months ago

Ascendis Pharma Reports Third Quarter 2025 Financial Results


Ascendis Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q2 2025


Ascendis Pharma Earnings release: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings release: Q2 2025


Ascendis Pharma Transcript: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Transcript: Study Update


Ascendis Pharma Press release: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Press release: Study Update


Ascendis Pharma Slides: Study Update

Jun 9, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Study Update


FDA Accepts TransCon® CNP NDA for Priority Review

Jun 2, 2025, 8:00 AM EDT - 1 year ago

FDA Accepts TransCon® CNP NDA for Priority Review


Ascendis Pharma Slides: Investor Presentation

May 15, 2025, 8:00 AM EDT - 1 year ago

Ascendis Pharma Slides: Investor Presentation


Ascendis Pharma Earnings Call Transcript: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings Call Transcript: Q1 2025


Ascendis Pharma Earnings release: Q1 2025

May 1, 2025, 4:30 PM EDT - 1 year ago

Ascendis Pharma Earnings release: Q1 2025


Ascendis Pharma Reports First Quarter 2025 Financial Results

May 1, 2025, 4:01 PM EDT - 1 year ago

Ascendis Pharma Reports First Quarter 2025 Financial Results


JamesTaulman
JamesTaulman Aug. 3 at 2:28 PM
MON 8/3: $ASND – CALLING A 2ND SELL SIGNAL @ $240.85 -4.0% 9:37 AM – Calling a 2ND SELL SIGNAL this morning (correction: the earlier email incorrectly stated a 1st SELL SIGNAL) as shares are clearly breaking below the 50 DMA. This loss of a major support level represents a meaningful technical violation and warrants further reducing the position. ULTRA Trader’s Tip: Major Support Levels Matter • The 50 DMA often serves as an important line of institutional support. • When a stock decisively breaks below that level, the probability of continued weakness increases. • Respecting major technical violations early helps preserve capital and keeps small losses from becoming much larger ones. https://buyingbreakouts.com/mon-8-3-asnd-calling-a-2nd-sell-signal-240-85-4-0/
0 · Reply
JamesTaulman
JamesTaulman Aug. 1 at 3:16 AM
FRI 7/31: $ASND – Any Further Declines Would Be the Final Sell Signal 7:50 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-7-31-asnd-any-further-declines-would-be-the-final-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 31 at 2:11 AM
THU 7/30: $ASND – A Break of the 50 DMA at $244.50 is a Long Overdue Sell Signal 7:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-30-asnd-a-break-of-the-50-dma-at-244-50-is-a-long-overdue-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 29 at 3:27 AM
TUE 7/28: $ASND – Rallies Into the Close but Remains Below Its Proven 10 DMA Resistance 8:30 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-7-28-asnd-rallies-into-the-close-but-remains-below-its-proven-10-dma-resistance/
0 · Reply
SenefAS
SenefAS Jul. 28 at 3:10 PM
When is the buyout and this high premium for Ascendis $ASND ? @bharringtonw11 $XBI $NVO
0 · Reply
JamesTaulman
JamesTaulman Jul. 28 at 2:04 AM
MON 7/27: $ASND – Makes for a Great Example of 10 DMA Resistance 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-27-asnd-makes-for-a-great-example-of-10-dma-resistance/
0 · Reply
JamesTaulman
JamesTaulman Jul. 25 at 4:02 AM
FRI 7/24: $ASND – The 10 DMA Just Keeps Crushing This Stock – a Break of the Round-$250 Would Be a Sell Signal 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-7-24-asnd-the-10-dma-just-keeps-crushing-this-stock-a-break-of-the-round-250-would-be-a-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 24 at 2:16 AM
THU 7/23: $ASND – Remains Above Our Noted Support of the Round-$250 – the 10 DMA Line Has Clearly Rolled Over – Not Good 8:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-23-asnd-remains-above-our-noted-support-of-the-round-250-the-10-dma-line-has-clearly-rolled-over-not-good/
0 · Reply
Quantumup
Quantumup Jul. 23 at 6:44 PM
Morgan Stanley, in a broad research note earnings preview, ⬆️ $ASND to $275 from $256, reiterated (reit'd) Overweight; $DNLI to $36 from $35, reit'd Overweight; $EXEL to $53 from $50, reit'd Equal Weight; and $INCY to $104 from $103, reit'd Equal Weight, and said 2Q26 earnings should reinforce a shift from macro-driven trading toward stock-specific execution and differentiation.
0 · Reply
JamesTaulman
JamesTaulman Jul. 23 at 3:05 AM
WED 7/22: $ASND – A Break Below the Round-$250 Would Be a 2nd Sell Signal 9:20 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-22-asnd-a-break-below-the-round-250-would-be-a-2nd-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 21 at 2:59 AM
$ASND – MON: Sold Off Today – Volume Lighter – a Break of the Round-$250 Would Be a 2nd Sell Signal 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List.\ https://buyingbreakouts.com/mon-7-20-asnd-sold-off-today-volume-lighter-a-break-of-the-round-250-would-be-a-2nd-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 18 at 2:26 AM
$ASND – FRI: Turned Back From the Rollin Over 10 DMA – Not Good 9:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/fri-7-17-asnd-turned-back-from-the-rollin-over-10-dma-not-good/
0 · Reply
JamesTaulman
JamesTaulman Jul. 16 at 1:55 AM
$ASND – WED: Gains Today Yet Remains Below the Recently Lost 10 DMA – Not Great 8:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-15-asnd-gains-today-yet-remains-below-the-recently-lost-10-dma-not-great/
0 · Reply
JamesTaulman
JamesTaulman Jul. 15 at 3:23 AM
$ASND – TUE: A Break Below the Recent Low of $262.00 Would Be a 2nd Sell Signal 9:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-7-14-asnd-a-break-below-the-recent-low-of-262-00-would-be-a-2nd-sell-signal/
0 · Reply
JamesTaulman
JamesTaulman Jul. 14 at 2:47 AM
$ASND – MON: Dropped Below Its 10 DMA and Triggered a Sell Signal +5.6% 9:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/mon-7-13-asnd-dropped-below-its-10-dma-and-triggered-a-sell-signal-5-6/
0 · Reply
JamesTaulman
JamesTaulman Jul. 13 at 2:31 PM
$ASND – MON: CALLING A 1ST SELL SIGNAL @ $265.12 +5.6% 10:02 AM – Calling a 1ST SELL SIGNAL this morning as shares are breaking below the 10 DMA. That is a standard technical violation and triggers an initial SELL SIGNAL under our rules. ULTRA Trader’s Tip: The 10 DMA Provides an Early Warning • Strong stocks often use the 10 DMA as support during healthy advances. • A clear break below that line signals weakening short-term momentum. • Taking partial profits on the initial violation helps protect gains while leaving room for the stock to recover. https://buyingbreakouts.com/mon-7-13-asnd-calling-a-1st-sell-signal-265-12-5-6/
0 · Reply
JamesTaulman
JamesTaulman Jul. 10 at 3:27 AM
$ASND – THU: Posts Amid Negative Reversal – Watching the 10 DMA at $268.25 10:00 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/thu-7-9-asnd-posts-amid-negative-reversal-watching-the-10-dma-at-268-25/
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech Jul. 9 at 11:25 PM
This is an update to our $ACAD v $PTCT post from a few weeks ago. Both have gained 20-25% since 6/10/26 when the $XBI began its recent surge. Analysts project ACAD to slightly outsell PTCT over the next 5 & 10 years. Both generate the same gross margins yet ACAD's market cap & enterprise value are roughly half of PTCT. The objective of this post is to ID the disconnect between the 2. This is not to bash PTCT (which incidentally trades at lower multiples than peers with more recent approvals like $INSM & $ASND ). We'd genuinely appreciate a PTCT perspective. We added analyst EPS estimates & related multiples that identify the same disconnect in valuation. Genuine feedback would be sincerely appreciated. This is not investment advice.
2 · Reply
JamesTaulman
JamesTaulman Jul. 9 at 3:05 AM
$ASND – WED: Posts Gains From the 10 DMA to a New High Close per Volume Only Average 9:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/wed-7-8-asnd-posts-gains-from-the-10-dma-to-a-new-high-close-per-volume-only-average/
0 · Reply
JamesTaulman
JamesTaulman Jul. 8 at 3:40 AM
$ASND – TUE: Closed Off of the Day Highs Yet Remains Above Support of the 10 DMA 10:15 PM – Here is our latest chart update for this recent breakout from our Traditional BreakOuts Watch List. https://buyingbreakouts.com/tue-7-7-asnd-closed-off-of-the-day-highs-yet-remains-above-support-of-the-10-dma/
0 · Reply
Buysidetrader69
Buysidetrader69 Jul. 7 at 5:32 PM
$BCRX WEDBUSH has a $21 price tgt on $BCRX They made comments earlier that $ASND and $BCRX are ripe to be bought
0 · Reply
JFDI
JFDI Jul. 7 at 3:49 PM
$ASND pretty
0 · Reply